Readnour Rob's most recent trade in AN2 Therapeutics Inc was a trade of 19,111 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Rob Readnour | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 19,111 | 19,111 | - | - | Stock Option (Right to Buy) | |
| AN2 Therapeutics Inc | Rob Readnour | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 9,077 | 9,077 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 06 Dec 2024 | 18,483 | 647,573 | - | 1.4 | 26,407 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.44 per share. | 06 Dec 2024 | 12,711 | 564,999 | - | 1.4 | 18,367 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 06 Dec 2024 | 12,289 | 577,288 | - | 1.4 | 17,577 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.45 per share. | 06 Dec 2024 | 6,517 | 629,090 | - | 1.4 | 9,427 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.49 per share. | 06 Dec 2024 | 5,000 | 652,573 | - | 1.5 | 7,468 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.49 per share. | 06 Dec 2024 | 5,000 | 582,288 | - | 1.5 | 7,462 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.42 per share. | 26 Nov 2024 | 25,000 | 552,288 | - | 1.4 | 35,423 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.42 per share. | 26 Nov 2024 | 25,000 | 622,573 | - | 1.4 | 35,418 | Common Stock |
| AN2 Therapeutics Inc | Readnour Rob | Director | Purchase of securities on an exchange or from another person at price $ 1.39 per share. | 26 Nov 2024 | 12,500 | 527,288 | - | 1.4 | 17,418 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.39 per share. | 26 Nov 2024 | 12,500 | 597,573 | - | 1.4 | 17,428 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.04 per share. | 19 Nov 2024 | 75,000 | 489,788 | - | 1.0 | 77,730 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.03 per share. | 19 Nov 2024 | 75,000 | 560,073 | - | 1.0 | 77,528 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.15 per share. | 19 Nov 2024 | 25,000 | 514,788 | - | 1.2 | 28,870 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 1.16 per share. | 19 Nov 2024 | 25,000 | 585,073 | - | 1.2 | 29,000 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 64,503 | 64,503 | - | - | Stock Option (Right to Buy) | |
| AN2 Therapeutics Inc | Readnour Rob | Director | Sale of securities on an exchange or to another person at price $ 21.91 per share. | 12 Jan 2024 | 719 | 485,073 | - | 21.9 | 15,753 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 12 Jan 2024 | 706 | 414,788 | - | 21.9 | 15,476 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Sale of securities on an exchange or to another person at price $ 21.93 per share. | 10 Jan 2024 | 1,869 | 415,494 | - | 21.9 | 40,987 | Common Stock |
| AN2 Therapeutics Inc | Readnour Rob | Director | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 10 Jan 2024 | 1,800 | 485,792 | - | 21.9 | 39,456 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 20,724 | 20,724 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Rob Readnour | Director | 29 Mar 2022 | 333,135 | 0 | - | - | Series A Convertible Preferred Stock | ||
| AN2 Therapeutics Inc | Rob Readnour | Director | 29 Mar 2022 | 333,135 | 333,135 | - | - | Common Stock | ||
| AN2 Therapeutics Inc | Rob Readnour | Director | 29 Mar 2022 | 285,156 | 0 | - | - | Series A Convertible Preferred Stock | ||
| AN2 Therapeutics Inc | Rob Readnour | Director | 29 Mar 2022 | 285,156 | 285,156 | - | - | Common Stock | ||
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 29 Mar 2022 | 82,618 | 487,592 | - | 15 | 1,239,270 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | 29 Mar 2022 | 71,839 | 0 | - | - | Series B Convertible Preferred Stock | ||
| AN2 Therapeutics Inc | Rob Readnour | Director | 29 Mar 2022 | 71,839 | 404,974 | - | - | Common Stock | ||
| AN2 Therapeutics Inc | Rob Readnour | Director | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 29 Mar 2022 | 70,716 | 417,363 | - | 15 | 1,060,740 | Common Stock |
| AN2 Therapeutics Inc | Rob Readnour | Director | 29 Mar 2022 | 61,491 | 0 | - | - | Series B Convertible Preferred Stock | ||
| AN2 Therapeutics Inc | Rob Readnour | Director | 29 Mar 2022 | 61,491 | 346,647 | - | - | Common Stock |